Blog

LOWERING DRUG PRICES FOR AMERICAN PATIENTS: Today, President Donald J. Trump announced nine new agreements with major pharmaceutical companies to lower prescription drug prices for Americans in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price).

• The nine manufacturers include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
• The agreements reduce prices on drugs that treat numerous costly and chronic conditions, including type two diabetes, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease (COPD), hepatitis B and C, human immunodeficiency virus (HIV), and certain cancers, among others.
• The agreements will provide every State Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings and continuing President Trump’s historic efforts to strengthen the program for the most vulnerable.
• The agreements ensure foreign nations can no longer use price controls to free ride on American innovation by guaranteeing MFN prices on all new innovative medicines the nine companies bring to market.
• The agreements require the nine companies to repatriate increased foreign revenue on existing products that they realize as a result of the President’s strong America First U.S. trade policies for the benefit of American patients.
• The agreements require the nine companies to offer medicines at a deep discount off the list price when selling directly to American patients through TrumpRx.

DELIVERING LOWER COSTS: Patients will be able to see massive price reductions on numerous products when purchasing directly through TrumpRx as a result of today’s actions. Select examples include:

• Amgen will reduce the price of its cholesterol-lowering drug Repatha from $573 to $239 for patients purchasing directly through TrumpRx.
• Bristol Myers Squibb will reduce the price of its HIV medication, Reyataz, from $1,449 to $217 for patients purchasing directly through TrumpRx.
• Boehringer Ingelheim will reduce the price of its type two diabetes medication, Jentadeuto, from $525 to $55 for patients purchasing directly through TrumpRx.
• Genentech will reduce the price of its flu medication, Xofluza, from $168 to $50 for patients purchasing directly through TrumpRx.
• Gilead Sciences will reduce the price of its Hepatitis C medication, Epclusa, from $24,920 to $2,425 for patients purchasing directly through TrumpRx.
• GSK will reduce the prices of its inhaler portfolio. Prices for the popular asthma inhaler Advair Diskus 500/50 will fall from $265 to $89 for patients purchasing directly through TrumpRx.
• Merck will reduce the price of its diabetes medication, Januvia, from $330 to $100 for patients purchasing directly through TrumpRx.
• Novartis will reduce the price of its Multiple Sclerosis medication, Mayzent, from $9,987 to $1,137 for patients purchasing directly through TrumpRx.
• Sanofi will reduce the price of its prescription blood thinner, Plavix, from $756 to $16 for patients purchasing directly through TrumpRx and Sanofi will list its insulin products at TrumpRx at $35 per month’s supply.

BOLSTERING NATIONAL HEALTH SECURITY BY INVESTING IN AMERICA: The pharmaceutical manufacturers involved in today’s announcement are committing to invest at least $150  billion collectively in U.S. manufacturing in the near term. Additionally, as part of the agreements, several companies are donating active pharmaceutical ingredients for key products to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR) to reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency.

December 19, 2025 | Austin, Texas
|

Press Release

Governor Greg Abbott today announced that Loloi, Inc., a textile brand leader, is building a distribution facility of more than 1 million square feet in Ennis, creating more than 380 new jobs and $20 million in capital investment as part of a multi-phase distribution headquarters development. A Texas Enterprise Fund (TEF) grant of $2,451,000 has been extended to Loloi. In addition, the company has been offered a $45,000 Veteran Created Job Bonus.

“Texas is where the crossroads of hard work and opportunity lead to success,” said Governor Abbott. “This $20 million investment by Loloi in Ennis just south of Dallas will create hundreds of good-paying jobs for hardworking Texans. With robust infrastructure and transportation networks providing easy access to key markets, Texas offers unmatched operating advantages for companies looking to expand. There truly is no better place than Texas to live, work, build a business, and raise a family.”

Headquartered in Dallas since its founding in 2003, Loloi is a family-owned wholesale producer and distributor of designer rugs, pillows, and throws and is expanding into other home furnishing categories.

“Texas has been our home since we started Loloi more than 20 years ago, and the state continues to provide opportunities to grow,” said Loloi Founder and President Amir Loloi. “This new facility in Ennis will allow us to add more jobs and create a world-class facility that we are proud of.”

“The City of Ennis is honored to welcome Loloi, Inc. as they expand their operations here in our community,” said Ennis Mayor Kameron Raburn. “This investment, made possible through the support of the Texas Enterprise Fund, represents not only new jobs and economic growth for our city, but also a strong vote of confidence in the talented workforce and vibrant business climate we’ve built in Ennis. We are grateful for Governor Abbott’s leadership and the partnership of the Texas Economic Development & Tourism Office in helping bring this opportunity to fruition.”

“This announcement reflects the cumulative work that has gone into creating opportunity in Ennis through partnerships and long-term vision,” said Ennis Economic Development Corporation Director Miriam Castillo. “Loloi’s footprint and associated investment mark a meaningful expansion of our region’s industrial base.”

View more information about Loloi.  

TEF is a performance-based grant that may be awarded to a business relocation or expansion project for which one Texas site is in competition with out-of-state locations to create new, good-paying jobs in the community and attract significant new capital investment to the state.